Crizotinib

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Crizotinib (PF-02341066;PF-2341066)is a potent, selective, orally bioavailable, ATP-competitive inhibitor of c-Met catalytic activity with Ki of 4 nM.

Crizotinib (PF-02341066;PF-2341066)is a potent, selective, orally bioavailable, ATP-competitive inhibitor of c-Met catalytic activity with Ki of 4 nM; displays >1,000-fold selective for the VEGFR2 and PDGFRβ RTKs, >250-fold selective for IRK and Lck, and ～40- to 60-fold selective for Tie2, TrkA, and TrkB; also inhibits ALK (IC50=24 nM), potently inhibits c-Met phosphorylation and c-Met-dependent proliferation, migration, or invasion of human tumor cells in vitro (IC50=5-20 nM); shows antitumor efficacy in tumor models at well-tolerated doses in vivo.Lung Cancer Approved

PF-02341066;PF-2341066

Angiogenesis

ALK

ALK;c-Met

Cancer

Lung Cancer

877399-52-5

450.34

C21H22Cl2FN5O

>98% (HPLC)

DMSO: 55 mg/mL (Need ultrasonic)

C[C@H](C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N

2-Pyridinamine, 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-

(-20℃)

With Ice Pack

≥ 2 years